Abstract:Glycosylation of the immunoglobulin G (IgG)-Fc tail is required for binding to Fc-gamma receptors (FcγRs) and complement-component C1q. A variety of IgG1-glycoforms is detected in human sera. Several groups have found global or antigen-specific skewing of IgG glycosylation, for example in autoimmune diseases, viral infections, and alloimmune reactions. The IgG glycoprofiles seem to correlate with disease outcome. Additionally, IgG-glycan composition contributes significantly to Ig-based therapies, as for example IVIg in autoimmune diseases and therapeutic antibodies for cancer treatment. The effect of the different glycan modifications, especially of fucosylation, has been studied before. However, the contribution of the 20 individual IgG glycoforms, in which the combined effect of all 4 modifications, to the IgG function has never been investigated. Here, we combined six glyco-engineering methods to generate all 20 major human IgG1-glycoforms and screened their functional capacity for FcγR and complement activity. Bisection had no effect on FcγR or C1q-binding, and sialylation had no- or little effect on FcγR binding. We confirmed that hypo-fucosylation of IgG1 increased binding to FcγRIIIa and FcγRIIIb by ~17-fold, but in addition we showed that this effect could be further increased to ~40-fold for FcγRIIIa upon simultaneous hypo-fucosylation and hyper-galactosylation, resulting in enhanced NK cell-mediated antibody-dependent cellular cytotoxicity. Moreover, elevated galactosylation and sialylation significantly increased (independent of fucosylation) C1q-binding, downstream complement deposition, and cytotoxicity. In conclusion, fucosylation and galactosylation are primary mediators of functional changes in IgG for FcγR- and complement-mediated effector functions, respectively, with galactose having an auxiliary role for FcγRIII-mediated functions. This knowledge could be used not only for glycan profiling of clinically important (antigen-specific) IgG but also to optimize therapeutic antibody applications.

Crystal Structure Of Sialylated Igg Fc: Implications For The Mechanism Of Intravenous Immunoglobulin Therapy

Molecular Recognition of Fc-Specific Ligands Binding Onto the Consensus Binding Site of Igg: Insights from Molecular Simulation

Dissecting the Molecular Mechanism of IVIg Therapy: the Interaction Between Serum IgG and DC-SIGN is Independent of Antibody Glycoform or Fc Domain.

Effects of Anchor Structure and Glycosylation of Fc Gamma Receptor Iii on Ligand Binding Affinity

NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation.

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity

Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases

Structural Insights into Immunoglobulin M

Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped During Glycan Biosynthesis

IgG sialylation occurs in B cells pre antibody secretion

B-cell–independent sialylation of IgG

An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin

Structural and biochemical requirements for secretory component interactions with dimeric Immunoglobulin A

3D Structures of IgA, IgM, and Components

Effects of N-glycans on the structure of human IgA2

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities

Impact of Immune Complex Size and Glycosylation on IgG Binding to Human FcγRs

Engineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal Antibodies

Hinge Disulfides in Human IgG2 CD40 Antibodies Modulate Receptor Signaling by Regulation of Conformation and Flexibility

Interchain Disulfide Bonding in Human IgG2 Antibodies Probed by Site-Directed Mutagenesis

Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1